Novartis AG ADR (NVS)vsRidgetech, Inc. (RDGT)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
RDGT
Ridgetech, Inc.
$0.83
-1.59%
HEALTHCARE · Cap: $3.39M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 42796% more annual revenue ($56.69B vs $132.16M). NVS leads profitability with a 22.5% profit margin vs -0.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RDGT
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+82.8%
Fair Value
$10.36
Current Price
$0.83
$9.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Every $100 of equity generates 30 in profit
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : RDGT
The strongest argument for RDGT centers on Price/Book, Return on Equity, Debt/Equity. Revenue growth of 21.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RDGT
The primary concerns for RDGT are EPS Growth, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
NVS profiles as a value stock while RDGT is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
RDGT is growing revenue faster at 21.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 39/100), backed by strong 22.5% margins. RDGT offers better value entry with a 82.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Ridgetech, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
China Jo-Jo Drugstores, Inc. is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company is headquartered in Hangzhou, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?